ANIX (Anixa Biosciences) FCF Yield %: -7.94 (As of Jun. 26, 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $2.64
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences FCF Yield %?

Anixa Biosciences ANIX -2.60% 27 FCF Yield % is -7.94 as of Jun. 26, 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,418 Biotechnology companies, Anixa Biosciences ranks better than 53.81% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Anixa Biosciences's Trailing 12-Month Free Cash Flow is $-7.12 Mil, and Market Cap is $89.65 Mil. Therefore, Anixa Biosciences's FCF Yield % for today is -7.94%.

The historical rank and industry rank for Anixa Biosciences's FCF Yield % or its related term are showing as below:

ANIX' s FCF Yield % Range Over the Past 10 Years
Min: -46.15   Med: -6.39   Max: -2.75
Current: -7.94


During the past 13 years, the highest FCF Yield % of Anixa Biosciences was -2.75%. The lowest was -46.15%. And the median was -6.39%.

ANIX's FCF Yield % is ranked better than
53.81% of 1418 companies
in the Biotechnology industry
Industry Median: -9.715 vs ANIX: -7.94

Anixa Biosciences's FCF Margin % for the quarter that ended in Apr. 2026 was 0.00%.


Anixa Biosciences FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Anixa Biosciences FCF Yield % Related Terms


Anixa Biosciences FCF Yield % Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences FCF Yield % Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.44 -3.75 -6.31 -6.51 -5.26

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.69 -6.02 -3.68 -10.26 -6.84

ANIX vs PYPD, LONA, SGMO: FCF Yield % Comparison

For the Biotechnology subindustry, Anixa Biosciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's FCF Yield % falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Anixa Biosciences's FCF Yield % for the fiscal year that ended in Oct. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-7.173 / 136.34782
=-5.26%

Anixa Biosciences's annualized FCF Yield % for the quarter that ended in Apr. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-1.741 * 4 / 101.769
=-6.84%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -7.94 mean?
Anixa Biosciences (ANIX) has a FCF Yield % of -7.94 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Anixa Biosciences and its competitors. According to the industry distribution chart, Anixa Biosciences ranks #655 out of 1418 companies in the Biotechnology industry, placing it in the top 46.2%.
Is Anixa Biosciences' FCF Yield % too high?
Anixa Biosciences' current FCF Yield % is -7.94. Based on the distribution chart, Anixa Biosciences ranks #655 out of 1418 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' FCF Yield % compare to PYPD and LONA?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #655 out of 1418 companies for FCF Yield %. This puts Anixa Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current FCF Yield % is -7.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current FCF Yield % of -7.94. The current FCF Yield % is -7.94. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current FCF Yield % is -7.94 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.64
Price